GlucoTrack, Inc. (NASDAQ:GCTK) shares are trading higher on Thursday after the company announced its subsidiary, Lōkahi Therapeutics, secured its first external fee-for-service partnership.

Innovate GBM, a nonprofit focused on glioblastoma research, engaged two Lokahi AI PIPELINE teams to identify brain tumor therapeutic assets for potential licensing and development.

The deal makes Innovate GBM the first external organization to use Lokahi’s proprietary asset-identification process, developed through 14 university collaborations.

Public Offering Pricing

Separately, the company announced the pricing of a "best efforts" public offering of 169,388 shares at $2.04 per share and pre-funded warrants for up to 1,350,220 shares at $2.039 per warrant.

The company expects gross proceeds of approximately $3.1 million before placement agent fees and offering expenses.

The offering was priced at the market under Nasdaq rules and is expected to close around Sept. 25, 2026, subject to customary closing conditions.

What GlucoTrack Does And Why Dilution Matters

GlucoTrack Inc is a medical device company focused on developing an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is advancing its Glucotrack CBGM system through clinical studies and regulatory processes, aiming to deliver continuous glucose monitoring using implantable sensor technology.

That backdrop matters today because early-stage med-tech developers often rely on external capital to fund trials and regulatory work, and equity offerings can create short-term stock pressure. In other words, the financing can help extend the runway, but traders often react first to dilution and added share supply.

GCTK Stock Price Action Today

GCTK Stock Price Activity: GlucoTrack shares were up 29.56% at $2.63 at the time of publication on Thursday, according to Benzinga Pro data.

See More: Top Value Stocks

Photo via Shutterstock